NO2914282T3 - - Google Patents

Info

Publication number
NO2914282T3
NO2914282T3 NO13811605A NO13811605A NO2914282T3 NO 2914282 T3 NO2914282 T3 NO 2914282T3 NO 13811605 A NO13811605 A NO 13811605A NO 13811605 A NO13811605 A NO 13811605A NO 2914282 T3 NO2914282 T3 NO 2914282T3
Authority
NO
Norway
Application number
NO13811605A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of NO2914282T3 publication Critical patent/NO2914282T3/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893Botulinum neurotoxin (3.4.24.69)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24Metalloendopeptidases (3.4.24)
    • C12Y304/24069Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO13811605A 2012-10-31 2013-10-31 NO2914282T3 (enEXAMPLES)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB201219602A GB201219602D0 (en) 2012-10-31 2012-10-31 Recombinant clostridium botulinum neurotoxins
PCT/GB2013/052845 WO2014068317A1 (en) 2012-10-31 2013-10-31 Recombinant clostridium botulinum neurotoxins

Publications (1)

Publication Number Publication Date
NO2914282T3 true NO2914282T3 (enEXAMPLES) 2018-05-19

Family

ID=47358958

Family Applications (1)

Application Number Title Priority Date Filing Date
NO13811605A NO2914282T3 (enEXAMPLES) 2012-10-31 2013-10-31

Country Status (26)

Country Link
US (1) US10030238B2 (enEXAMPLES)
EP (3) EP2914282B1 (enEXAMPLES)
JP (2) JP2019068823A (enEXAMPLES)
KR (2) KR102264478B1 (enEXAMPLES)
CN (2) CN110499321A (enEXAMPLES)
AR (2) AR093309A1 (enEXAMPLES)
AU (3) AU2013340610B2 (enEXAMPLES)
BR (1) BR112015005384A2 (enEXAMPLES)
CA (1) CA2885519A1 (enEXAMPLES)
DK (2) DK2914282T3 (enEXAMPLES)
EA (1) EA201590794A8 (enEXAMPLES)
ES (2) ES2788199T3 (enEXAMPLES)
GB (1) GB201219602D0 (enEXAMPLES)
HU (2) HUE036764T2 (enEXAMPLES)
IL (1) IL237623B (enEXAMPLES)
IN (1) IN2015MN00436A (enEXAMPLES)
MX (2) MX367080B (enEXAMPLES)
NO (1) NO2914282T3 (enEXAMPLES)
NZ (1) NZ705575A (enEXAMPLES)
PL (2) PL3326644T3 (enEXAMPLES)
PT (2) PT3326644T (enEXAMPLES)
SG (2) SG11201502372SA (enEXAMPLES)
TW (3) TW202012622A (enEXAMPLES)
UA (1) UA118837C2 (enEXAMPLES)
WO (1) WO2014068317A1 (enEXAMPLES)
ZA (1) ZA201501449B (enEXAMPLES)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201219602D0 (en) * 2012-10-31 2012-12-12 Syntaxin Ltd Recombinant clostridium botulinum neurotoxins
ES2895853T3 (es) * 2015-03-26 2022-02-22 Harvard College Neurotoxina botulínica modificada
WO2017063743A1 (en) 2015-10-14 2017-04-20 Merz Pharma Gmbh & Co. Kgaa Improvements to ultrasound-based therapy of photoaged tissue
KR20180114891A (ko) 2016-03-02 2018-10-19 메르츠 파마 게엠베하 운트 코. 카가아 보툴리눔 독소를 포함하는 조성물
EP3263710A1 (en) * 2016-07-01 2018-01-03 Ipsen Biopharm Limited Production of activated clostridial neurotoxins
WO2018039506A1 (en) 2016-08-24 2018-03-01 President And Fellows Of Harvard College Engineered botulinum neurotoxin
KR102558892B1 (ko) 2016-09-13 2023-07-21 알레간 인코포레이티드 안정화된 비단백질 클로스트리듐 독소 조성물
EP3642222A1 (en) 2017-06-20 2020-04-29 Merz Pharma GmbH & Co. KGaA Novel recombinant botulinum toxin with increased duration of effect
EP3649143B1 (en) 2017-07-06 2022-08-31 Merz Pharma GmbH & Co. KGaA Novel recombinant botulinum neurotoxins with increased duration of effect
AU2018347514C1 (en) 2017-10-11 2025-01-02 Illustris Pharmaceuticals, Inc. Methods and compositions for topical delivery
SG11202003671VA (en) * 2018-01-29 2020-08-28 Ipsen Biopharm Ltd Non-neuronal snare-cleaving botulinum neurotoxins
US11707510B2 (en) * 2018-02-16 2023-07-25 Preclinics Discovery Gmbh Nucleic acid-based botulinum neurotoxin for therapeutic use
GB201815844D0 (en) * 2018-09-28 2018-11-14 Ipsen Biopharm Ltd Therapeutic & comestic uses of botulinum neurotoxin serotype e
GB202011055D0 (en) 2020-07-17 2020-09-02 Ipsen Bioinnovation Ltd Treatment of post-operative pain
GB202015618D0 (en) * 2020-10-01 2020-11-18 Ipsen Biopharm Ltd Method for producing beta-trypsin
CN115819526A (zh) * 2022-12-02 2023-03-21 海雅美生物技术(珠海)有限公司 一种重组肉毒杆菌神经毒素及其制备方法和应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6967088B1 (en) * 1995-03-16 2005-11-22 Allergan, Inc. Soluble recombinant botulinum toxin proteins
NZ308772A (en) * 1995-05-17 1999-04-29 Du Pont Recombinant baculovirus insecticides
DE69937890D1 (de) 1998-07-10 2008-02-14 U S Army Medical Res Inst Of I Impfstoffe gegen neurotoxine von clostridium botulinum
ES2277854T5 (es) * 1999-08-25 2011-02-04 Allergan, Inc. Neurotoxinas recombinantes activables.
US7374896B2 (en) 2001-08-28 2008-05-20 Allergan, Inc. GFP-SNAP25 fluorescence release assay for botulinum neurotoxin protease activity
US7514088B2 (en) * 2005-03-15 2009-04-07 Allergan, Inc. Multivalent Clostridial toxin derivatives and methods of their use
US20110111483A1 (en) 2004-06-30 2011-05-12 Allergan, Inc. Optimizing Expression of Active Botulinum Toxin Type E
US7825233B2 (en) * 2004-06-30 2010-11-02 Allergan, Inc. Optimizing expression of active Botulinum Toxin type E
GB2416122A (en) * 2004-07-12 2006-01-18 Ipsen Ltd Botulinum neurotoxin composition
DE102004043009A1 (de) * 2004-09-06 2006-03-23 Toxogen Gmbh Transportprotein zum Einbringen chemischer Verbindungen in Nervenzellen
DE102005002978B4 (de) 2005-01-21 2013-04-25 Merz Pharma Gmbh & Co. Kgaa Rekombinante Expression von Proteinen in einer disulfidverbrückten, zweikettigen Form
KR20070115580A (ko) * 2005-03-03 2007-12-06 알러간, 인코포레이티드 클로스트리디움 박테리아를 위한 배지 및 클로스트리디움계독소를 얻기 위한 프로세스
WO2008008082A2 (en) * 2005-09-19 2008-01-17 Allergan, Inc. Clostridial toxin activatable clostridial toxins
US20070218084A1 (en) * 2005-12-30 2007-09-20 Fondazione Pierfranco E Luisa Mariani- Onlus Method for the Mapping of the Epileptogenic Focus in the Pre-Surgical Evaluation of Patients with Intractable Epilepsy
CA2657521A1 (en) * 2006-07-11 2008-01-17 Allergan, Inc. Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for non-clostridial toxin target cells
WO2009014854A1 (en) * 2007-07-26 2009-01-29 Allergan, Inc. Methods of activiting clostridial toxins
KR20160103551A (ko) * 2008-12-10 2016-09-01 알러간, 인코포레이티드 클로스트리디움 독소 약제학적 조성물
GB0903006D0 (en) * 2009-02-23 2009-04-08 Syntaxin Ltd Modified non-cytotoxic proteases
CN102481351B (zh) * 2009-04-14 2015-05-13 Mcw研究基金会股份有限公司 工程改造的肉毒杆菌神经毒素
WO2011142783A2 (en) * 2009-12-16 2011-11-17 Allergan, Inc. Modified clostridial toxins comprising an integrated protease cleavage site-binding domain
WO2012112434A1 (en) 2011-02-14 2012-08-23 Allergan, Inc. Inhibiting aberrant blood vessel formation using retargeted endopeptidases
GB201219602D0 (en) * 2012-10-31 2012-12-12 Syntaxin Ltd Recombinant clostridium botulinum neurotoxins
GB201407525D0 (en) * 2014-04-29 2014-06-11 Syntaxin Ltd Manufacture of recombinant clostridium botulinum neurotoxins
WO2018039506A1 (en) * 2016-08-24 2018-03-01 President And Fellows Of Harvard College Engineered botulinum neurotoxin

Also Published As

Publication number Publication date
JP2019068823A (ja) 2019-05-09
WO2014068317A1 (en) 2014-05-08
EA201590794A8 (ru) 2016-01-29
EP3326644A1 (en) 2018-05-30
CA2885519A1 (en) 2014-05-08
JP2020078321A (ja) 2020-05-28
KR102188539B1 (ko) 2020-12-09
PT2914282T (pt) 2018-03-13
EP3673914B1 (en) 2021-10-27
MX2019009222A (es) 2019-11-21
AU2020244481A1 (en) 2020-10-29
TWI626307B (zh) 2018-06-11
SG10201701140WA (en) 2017-04-27
DK3326644T3 (da) 2020-05-11
TW201435084A (zh) 2014-09-16
ZA201501449B (en) 2016-08-31
IN2015MN00436A (enEXAMPLES) 2015-09-04
NZ705575A (en) 2019-08-30
IL237623A0 (en) 2015-04-30
PT3326644T (pt) 2020-05-29
UA118837C2 (uk) 2019-03-25
CN104755098A (zh) 2015-07-01
AU2018203556A1 (en) 2018-06-07
AR117738A2 (es) 2021-08-25
AU2018203556B2 (en) 2020-08-20
EP3326644B1 (en) 2020-03-04
EA201590794A1 (ru) 2015-08-31
ES2662402T3 (es) 2018-04-06
HUE036764T2 (hu) 2018-07-30
EP3673914A1 (en) 2020-07-01
EP2914282B1 (en) 2017-12-20
GB201219602D0 (en) 2012-12-12
AR093309A1 (es) 2015-05-27
SG11201502372SA (en) 2015-05-28
AU2013340610A1 (en) 2015-03-19
KR20200110470A (ko) 2020-09-23
ES2788199T3 (es) 2020-10-20
KR20150094590A (ko) 2015-08-19
AU2013340610B2 (en) 2018-02-22
CN110499321A (zh) 2019-11-26
KR102264478B1 (ko) 2021-06-15
PL2914282T3 (pl) 2018-07-31
EP2914282A1 (en) 2015-09-09
DK2914282T3 (en) 2018-02-26
US20150247139A1 (en) 2015-09-03
TW201825680A (zh) 2018-07-16
PL3326644T3 (pl) 2020-08-24
MX367080B (es) 2019-08-05
US10030238B2 (en) 2018-07-24
TWI673361B (zh) 2019-10-01
IL237623B (en) 2019-05-30
HUE048802T2 (hu) 2020-08-28
MX2015005156A (es) 2015-09-23
BR112015005384A2 (pt) 2017-08-08
TW202012622A (zh) 2020-04-01
HK1208359A1 (en) 2016-03-04

Similar Documents

Publication Publication Date Title
BR112014017635A2 (enEXAMPLES)
BR112014017614A2 (enEXAMPLES)
BR112014017708A2 (enEXAMPLES)
BR112014017625A2 (enEXAMPLES)
BR112014021401A2 (enEXAMPLES)
BR112014017659A2 (enEXAMPLES)
BR112014017592A2 (enEXAMPLES)
BR112014019235A2 (enEXAMPLES)
BR112014017646A2 (enEXAMPLES)
BR112014019610A2 (enEXAMPLES)
BR112014017638A2 (enEXAMPLES)
BR112014017607A2 (enEXAMPLES)
BR112014017609A2 (enEXAMPLES)
BR112014017634A2 (enEXAMPLES)
BR112014017644A2 (enEXAMPLES)
BR112014017618A2 (enEXAMPLES)
BR112014017647A2 (enEXAMPLES)
BR112014017623A2 (enEXAMPLES)
BR112014025069A2 (enEXAMPLES)
BR112014017630A2 (enEXAMPLES)
BR112014017652A2 (enEXAMPLES)
BR112014024269A2 (enEXAMPLES)
BR112014017631A2 (enEXAMPLES)
BR112014017641A2 (enEXAMPLES)
BR112014017627A2 (enEXAMPLES)